Repligen (RGEN) Stock Forecast & Price Target

Compare

976 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGEN Analyst Ratings

Strong Buy

11 Buy

3 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Repligen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGEN Stock 12 Month Forecast

Average Price Target

$188.20

▲(15.90% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is $188.20 with a high forecast of $220.00 and a low forecast of $150.00. The average price target represents a 15.90% change from the last price of $162.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"117":"$117","143":"$143","169":"$169","195":"$195","221":"$221"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$220.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":188.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$188.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$150.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[117,143,169,195,221],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.35,170.47692307692307,174.60384615384615,178.73076923076923,182.8576923076923,186.98461538461538,191.11153846153846,195.23846153846154,199.3653846153846,203.4923076923077,207.61923076923077,211.74615384615385,215.87307692307692,{"y":220,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.35,168.03076923076924,169.71153846153845,171.3923076923077,173.0730769230769,174.75384615384615,176.43461538461537,178.1153846153846,179.79615384615383,181.47692307692307,183.1576923076923,184.83846153846153,186.51923076923077,{"y":188.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.35,165.09230769230768,163.83461538461538,162.57692307692307,161.31923076923076,160.06153846153845,158.80384615384614,157.54615384615386,156.28846153846155,155.03076923076924,153.77307692307693,152.51538461538462,151.2576923076923,{"y":150,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":150.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$220.00

Average Price Target$188.20

Lowest Price Target$150.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Hewitt

Craig-Hallum

Buy

―

Reiterated

12/16/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Novan (NASDAQ: NOVN) and Repligen (NASDAQ: RGEN)

Brandon Couillard

Wells Fargo

$175→$190

Buy

17.01%

Upside

Reiterated

12/15/25

Repligen price target raised to $190 from $175 at Wells FargoRepligen price target raised to $190 from $175 at Wells Fargo

Casey Woodring

J.P. Morgan

$190

Buy

17.01%

Upside

Reiterated

12/15/25

J.P. Morgan Keeps Their Buy Rating on Repligen (RGEN)…we remain Overweight

Luke Sergott

Barclays

$175→$200

Buy

23.17%

Upside

Reiterated

12/15/25

Barclays Sticks to Their Buy Rating for Repligen (RGEN)

Daniel Arias

Stifel Nicolaus

$207

Buy

27.48%

Upside

Reiterated

11/12/25

Stifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)

Ram Selvaraju

H.C. Wainwright

$180

Buy

10.85%

Upside

Reiterated

11/03/25

H.C. Wainwright Remains a Buy on Repligen (RGEN)

Robert Wasserman

Benchmark Co.

Hold

―

Reiterated

10/29/25

Benchmark Co. Remains a Hold on Repligen (RGEN)

Daniel Markowitz CFA

Evercore ISI

$175→$180

Buy

10.85%

Upside

Reiterated

10/29/25

Evercore ISI Remains a Buy on Repligen (RGEN)

Kyle Mikson CFA

Canaccord Genuity

$150→$165

Hold

1.61%

Upside

Reiterated

10/29/25

Repligen (RGEN) Receives a Hold from Canaccord Genuity

Subbu Nambi

Guggenheim

Hold

―

Reiterated

10/28/25

Guggenheim Sticks to Their Hold Rating for Repligen (RGEN)

Brendan Smith

TD Cowen

$200

Buy

23.17%

Upside

Reiterated

10/28/25

Repligen's Strong Performance and Strategic Growth Initiatives Earn 'Buy' Rating

Matt Larew

William Blair

Buy

―

Reiterated

10/28/25

Repligen's Strong Q3 Performance and Upward Revenue Guidance Justify Buy Rating

Yessica Sanchez Gudino

HSBC

Not Ranked

HSBC

$150

Buy

-7.62%

Downside

Initiated

09/30/25

Repligen's Growth Potential: A Buy Rating Backed by Innovation and Strategic Positioning

Paul Knight

KeyBanc

$220

Buy

35.48%

Upside

Reiterated

09/23/25

KeyBanc Sticks to Their Buy Rating for Repligen (RGEN)

Puneet Souda

Leerink Partners

$200

Buy

23.17%

Upside

Reiterated

09/11/25

Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Insulet (PODD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Hewitt

Craig-Hallum

Buy

―

Reiterated

12/16/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Novan (NASDAQ: NOVN) and Repligen (NASDAQ: RGEN)

Brandon Couillard

Wells Fargo

$175→$190

Buy

17.01%

Upside

Reiterated

12/15/25

Repligen price target raised to $190 from $175 at Wells FargoRepligen price target raised to $190 from $175 at Wells Fargo

Casey Woodring

J.P. Morgan

$190

Buy

17.01%

Upside

Reiterated

12/15/25

J.P. Morgan Keeps Their Buy Rating on Repligen (RGEN)…we remain Overweight

Luke Sergott

Barclays

$175→$200

Buy

23.17%

Upside

Reiterated

12/15/25

Barclays Sticks to Their Buy Rating for Repligen (RGEN)

Daniel Arias

Stifel Nicolaus

$207

Buy

27.48%

Upside

Reiterated

11/12/25

Stifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)

Ram Selvaraju

H.C. Wainwright

$180

Buy

10.85%

Upside

Reiterated

11/03/25

H.C. Wainwright Remains a Buy on Repligen (RGEN)

Robert Wasserman

Benchmark Co.

Hold

―

Reiterated

10/29/25

Benchmark Co. Remains a Hold on Repligen (RGEN)

Daniel Markowitz CFA

Evercore ISI

$175→$180

Buy

10.85%

Upside

Reiterated

10/29/25

Evercore ISI Remains a Buy on Repligen (RGEN)

Kyle Mikson CFA

Canaccord Genuity

$150→$165

Hold

1.61%

Upside

Reiterated

10/29/25

Repligen (RGEN) Receives a Hold from Canaccord Genuity

Subbu Nambi

Guggenheim

Hold

―

Reiterated

10/28/25

Guggenheim Sticks to Their Hold Rating for Repligen (RGEN)

Brendan Smith

TD Cowen

$200

Buy

23.17%

Upside

Reiterated

10/28/25

Repligen's Strong Performance and Strategic Growth Initiatives Earn 'Buy' Rating

Matt Larew

William Blair

Buy

―

Reiterated

10/28/25

Repligen's Strong Q3 Performance and Upward Revenue Guidance Justify Buy Rating

Yessica Sanchez Gudino

HSBC

Not Ranked

HSBC

$150

Buy

-7.62%

Downside

Initiated

09/30/25

Repligen's Growth Potential: A Buy Rating Backed by Innovation and Strategic Positioning

Paul Knight

KeyBanc

$220

Buy

35.48%

Upside

Reiterated

09/23/25

KeyBanc Sticks to Their Buy Rating for Repligen (RGEN)

Puneet Souda

Leerink Partners

$200

Buy

23.17%

Upside

Reiterated

09/11/25

Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Insulet (PODD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

1 Month

xxx

Success Rate

12/20 ratings generated profit

Average Return

+3.19%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +3.19% per trade.

3 Months

xxx

Success Rate

14/25 ratings generated profit

Average Return

+5.94%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +5.94% per trade.

1 Year

Daniel AriasStifel Nicolaus

Success Rate

14/25 ratings generated profit

Average Return

+19.40%

reiterated a buy rating last month

Copying Daniel Arias's trades and holding each position for 1 Year would result in 56.00% of your transactions generating a profit, with an average return of +19.40% per trade.

2 Years

xxx

Success Rate

7/12 ratings generated profit

Average Return

+11.18%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.33% of your transactions generating a profit, with an average return of +11.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGEN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGEN has received 17 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. RGEN average Analyst price target in the past 3 months is 188.20.

Each month's total comprises the sum of three months' worth of ratings.

RGEN Financial Forecast

RGEN Earnings Forecast

Next quarter’s earnings estimate for RGEN is $0.44 with a range of $0.42 to $0.50. The previous quarter’s EPS was $0.46. RGEN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RGEN has Performed in-line its overall industry.

RGEN Sales Forecast

Next quarter’s sales forecast for RGEN is $192.64M with a range of $189.00M to $194.25M. The previous quarter’s sales results were $188.81M. RGEN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RGEN has Performed in-line its overall industry.

RGEN Stock Forecast FAQ

What is RGEN’s average 12-month price target, according to analysts?

Based on analyst ratings, Repligen Corp’s 12-month average price target is 188.20.

What is RGEN’s upside potential, based on the analysts’ average price target?

Repligen Corp has 15.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RGEN a Buy, Sell or Hold?

Repligen Corp has a consensus rating of Strong Buy which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.

What is Repligen Corp’s price target?

The average price target for Repligen Corp is 188.20. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $220.00 ,the lowest forecast is $150.00. The average price target represents 15.90% Increase from the current price of $162.38.

What do analysts say about Repligen Corp?

Repligen Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of RGEN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Repligen (RGEN) Stock Forecast & Price Target

RGEN Analyst Ratings

RGEN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Repligen

RGEN Analyst Recommendation Trends

RGEN Financial Forecast

RGEN Earnings Forecast

RGEN Sales Forecast

RGEN Stock Forecast FAQ

Detailed List of Analyst Forecasts